Bioretec Ltd., a top company in absorbable orthopedic implants, has officially named Sarah van Hellenberg Hubar-Fisher as its new Chief Executive Officer, effective immediately. She has been acting as CEO since May 2025 and has been part of the company’s Board of Directors since 2021. With a strong background in medtech leadership, van Hellenberg Hubar-Fisher is taking on this role with a focus on growing Bioretec’s business after key regulatory successes.
Health Technology Insights: Sonoma Biotherapeutics Appoints Lisa Taylor Ash, as Chief Legal Officer
Following her appointment, van Hellenberg Hubar-Fisher will step down from her positions on the Board of Directors, including Vice Chairperson and member of the Audit Committee. The Board has selected Antti Vasara to take over these roles as the new Vice Chairman and Audit Committee member.
Kustaa Poutiainen, Chairperson of Bioretec’s Board, praised Sarah’s leadership, pointing out her wide experience in healthcare and her success in introducing new technologies worldwide. He highlighted her effective leadership during her interim CEO tenure and expressed confidence in her ability to guide Bioretec toward becoming a global leader in innovative absorbable orthopedic implants.
Health Technology Insights: Devonian Issues Corporate Update and Private Placement Information
Sarah van Hellenberg Hubar-Fisher expressed enthusiasm about her new role and the company’s future. She outlined her priorities, including accelerating the global launch of the RemeOs implant, building on the strong performance of the Activa product, and ensuring both products have the resources needed to grow efficiently. With RemeOs now CE-marked and Activa continuing to perform well, she believes Bioretec is well-positioned to expand its market presence, deliver strong clinical results, and create lasting value for shareholders.
Van Hellenberg Hubar-Fisher brings over 23 years of leadership experience in healthcare, medtech, and global public health. She has a proven record of turning innovative ideas into practical solutions, launching new ventures, and driving international growth. Besides her role at Bioretec, she serves on the Board of Global Surgical Initiatives, a nonprofit focused on providing surgical care to underserved communities. Her past roles include senior positions at Johnson & Johnson and venture partner roles at Nina Capital in Spain and Growth Science Ventures in the US. She holds an MBA in Entrepreneurship from Babson College and a postgraduate degree in Global Business from the University of Oxford.
Health Technology Insights: Biofrontera Completes Phase 2b Study of Ameluz for Acne Vulgaris
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
